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background
 
The effectiveness of avoidance of house-dust-mite allergen (
 
Dermatophagoides ptero-
nyssinus
 
 1 [Der p1]) in the management of asthma is uncertain.
 
methods
 
We conducted a double-blind, randomized, placebo-controlled study of allergen-imper-
meable bed covers involving 1122 adults with asthma. The primary outcomes were the
mean morning peak expiratory flow rate over a four-week period during the run-in phase
and at six months and the proportion of patients who discontinued inhaled corticoster-
oid therapy as part of a phased-reduction program during months 7 through 12. Der p1
was measured in mattress dust in a 10 percent random subsample of homes at entry
and at 6 and 12 months.
 
results
 
The prevalence of sensitivity to dust-mite allergen was 65.4 percent in the group sup-
plied with allergen-impermeable bed covers (active-intervention group) and 65.1 per-
cent in the control group supplied with non-impermeable bed covers. The concentration
of Der p1 in mattress dust was significantly lower in the active-intervention group at
6 months (geometric mean, 0.58 µg per gram vs. 1.71 µg per gram in the control group;
P=0.01) but not at 12 months (1.05 µg per gram vs. 1.64 µg per gram; P=0.74). The
mean morning peak expiratory flow rate improved significantly in both groups (from
410.7 to 419.1 liters per minute in the active-intervention group, P<0.001 for the change;
and from 417.8 to 427.4 liters per minute in the control group, P<0.001 for the change).
After adjustment for base-line differences (by analysis of covariance), there was no sig-
nificant difference between the groups in the peak expiratory flow rate at six months
(difference in means, active-intervention group vs. control group, ¡1.6 liters per minute
[95 percent confidence interval, ¡5.9 to 2.7] among all patients [P=0.46] and ¡1.5 liters
per minute [95 percent confidence interval, ¡6.9 to 3.9] among mite-sensitive patients
[P=0.59]). There was no significant difference between the groups in the proportion in
whom complete cessation of inhaled corticosteroid therapy was achieved (17.4 percent
in the active-intervention group and 17.1 percent in the control group) or in the mean
reduction in steroid dose, either among all patients or among mite-sensitive patients.
 
conclusions
 
Allergen-impermeable covers, as a single intervention for the avoidance of exposure to
dust-mite allergen, seem clinically ineffective in adults with asthma.
abstract
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xposure to high levels of dust-
 
mite allergen among patients with asthma
who are allergic to dust mites is associat-
ed with greater severity of disease and increased
use of health care,
 
1,2
 
 but the clinical effectiveness
of avoidance of mite allergen by patients with asth-
ma remains controversial. Removal of mite-sensitive
children with asthma from their homes to the low-
allergen environment of high-altitude sanitariums
improves airway reactivity and reduces airway in-
flammation,
 
3,4
 
 but other factors besides the avoid-
ance of mites may be responsible for these improve-
ments.
There are conflicting data on the effectiveness
of domestic mite-allergen control in patients with
asthma.
 
5-11
 
 It also remains unclear whether a ma-
jor reduction in personal exposure, similar to that
achieved at high altitudes, can be achieved in homes.
Since mite allergens become airborne only after the
disturbance of dust, it seems likely that most expo-
sure occurs in bed. In recent years, comfortable wa-
ter-vapor–permeable, mite-allergen–impermeable
bed covers have been marketed that substantially re-
duce the level of exposure to allergen in bed.
 
12
 
 In a
pragmatic, randomized trial involving typical adult
patients with asthma in primary care, we tested the
hypothesis that allergen-impermeable bed covers
improve asthma control.
 
study design
 
We conducted a randomized, parallel-group, dou-
ble-blind, placebo-controlled trial of mite-allergen
avoidance (with the use of allergen-impermeable
covers for mattresses, pillows, and quilts or identi-
cal-appearing covers that were not impermeable to
mite allergen) among adult patients with asthma
who were registered with 154 general practices in
the Medical Research Council’s General Practice Re-
search Framework. The multicenter research ethics
committee and all the local research ethics commit-
tees approved the study. All patients gave written
informed consent.
 
study participants
 
Letters of invitation were sent to all patients 18 to
50 years of age with physician-diagnosed asthma
who were regularly taking inhaled corticosteroids
and were enrolled in participating practices. Patients
already using allergen-impermeable bed covers or
using less than 100 µg of albuterol per day or the
equivalent were excluded. At entry (before random-
ization), serum 
 
Dermatophagoides pteronyssinus
 
–spe-
cific IgE was measured in a central laboratory by
immunoassay (UniCAP, Pharmacia–Upjohn), and
sensitization was defined by a concentration of more
than 0.35 kU per liter.
 
13
 
 Patients and assessors were
unaware of the patients’ mite-sensitivity status. Ran-
domization was performed at the coordination cen-
ter, and the minimization technique was used to
generate the randomization schedule. The minimi-
zation procedure ensured balance between the ran-
domized groups within each practice and according
to pet ownership or nonownership, smoking status,
and mite-specific IgE levels.
 
study procedures
 
Consenting, eligible patients were randomly as-
signed to receive either mattress, pillow, and quilt
covers impermeable to 
 
D. pteronyssinus
 
 1 (Der p1)
(vapor-permeable Allergy Control barrier [Allergy
Control Products]) or non-impermeable polyester–
cotton (control) covers. The covers were fitted by
a research nurse and left on the bedding for one
year. No specific washing instructions for bed cov-
ers or any other information on the avoidance of
mites was given to patients in either group.
The homes of all patients were visited at the start
of the study, and the homes of a 10 percent random
sample of the patients were also visited at 6 and 12
months. Dust samples were collected by the vacu-
uming of a 1-m
 
2
 
 area of the mattress for two minutes
through a filter device (ALK). The samples were as-
sayed for Der p1 with the use of a two-site immu-
nometric enzyme-linked immunosorbent assay.
 
14
 
study schedule and outcomes
 
Patients who responded to the invitation completed
a screening questionnaire. Those who met the cri-
teria for inclusion were seen by study nurses and
completed a detailed questionnaire capturing data
on medication use, pet ownership, smoking history,
time spent away from home, and use of allergen-
impermeable covers. A blood sample was collect-
ed for measurement of serum mite-allergen–spe-
cific IgE.
Patients then commenced a four-week run-in
phase, during which they completed a diary card
documenting morning and evening peak expiratory
flow rate (recording the best of three efforts [Mini-
Wright flowmeter, Clement Clarke International]),
scores for daytime and nighttime symptoms, and
beta-agonist use. Those who satisfactorily complet-
e
methods
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Figure 1. Profile of the Trial.
1150 Total
1122 Total
1075 Total
1015 Total
965 Total
751 Total
932 Total
882 Total
Phase 2, Reduction in
Inhaled Corticosteroids
Prerandomization
Postrandomization, Phase 1
21,045 Patients received letters from 154 practices 
12,502 Replies received
4654 Interested
2479 Screened
1746 Eligible
1679 Wanted to take part
1431 Started run-in phase
1150 On randomization list
3133 Using inhaled relief medication ≥1 time/day and using corticosteroids
574 Given allergen-impermeable
bed covers
576 Given control bed covers
560 Received home visit 562 Received home visit
539 Had 3-mo follow-up 536 Had 3-mo follow-up
507 Had 6-mo follow-up 508 Had 6-mo follow-up
480 Completed 6-mo diary 485 Completed 6-mo diary
138 Did not enter dose-
reduction phase
126 Did not enter dose-
reduction phase
369 Entered dose-reduction phase 382 Entered dose-reduction phase
466 Had 12-mo follow-up 466 Had 12-mo follow-up
437 Completed 12-mo diary 445 Completed 12-mo diary
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Table 1. Base-Line Characteristics of the Study Population.*
Characteristic All Patients Mite-Sensitive Patients
 
Active-Intervention
Group 
(N=560)
Control
Group 
(N=562)
Active-Intervention
Group 
(N=366)
Control
Group 
(N=366)
Age — yr 36.4±8.4 36.9±8.2 35.4±8.0 35.9±8.0
Sex — no. (%)
Male 192 (34.3) 214 (38.1) 148 (40.4) 159 (43.4)
Female 368 (65.7) 348 (61.9) 218 (59.6) 207 (56.6)
Race — no. (%)†
White 548 (97.9) 552 (98.2) 359 (98.1) 359 (98.1)
Other 12 (2.1) 10 (1.8) 7 (1.9) 7 (1.9)
Smoking history — no. (%)
Ever smoked 254 (45.4) 281 (50.0) 149 (40.7) 177 (48.4)
Current smoker 131 (23.4) 134 (23.8) 70 (19.1) 80 (21.9)
Cat or dog owner — no. (%) 306 (54.6) 307 (54.6) 192 (52.5) 192 (52.5)
Mite-specific IgE level — no. (%)
<0.35 kU/liter 194 (34.6) 196 (34.9)
0.35–0.69 kU/liter 18 (3.2) 29 (5.2)
0.70–3.49 kU/liter 51 (9.1) 53 (9.4)
3.50–17.49 kU/liter 87 (15.5) 82 (14.6)
17.50–49.99 kU/liter 69 (12.3) 83 (14.8)
50.00–99.99 kU/liter 63 (11.2) 35 (6.2)
≥100.00 kU/liter 78 (13.9) 84 (14.9)
Concentration of Der p1 in mattress dust — no. (%)‡
<2 µg/g of dust 290 (51.8) 273 (48.6) 189 (51.6) 176 (48.2)
2–10 µg/g of dust 124 (22.1) 140 (25.0) 82 (22.4) 93 (25.5)
>10 µg/g of dust 146 (26.1) 148 (26.4) 95 (26.0) 96 (26.3)
Symptoms occurring at least once/day — no. (%)
Wheezing 205 (36.6) 225 (40.0) 129 (35.2) 144 (39.3)
Cough 231 (41.2) 227 (40.4) 124 (33.9) 129 (35.2)
Breathlessness 209 (37.3) 206 (36.7) 122 (33.3) 128 (35.0)
Chest tightness 139 (24.8) 155 (27.6) 98 (26.8) 96 (26.2)
Waking at night 81 (14.5) 91 (16.2) 51 (13.9) 46 (12.6)
Inability to participate in activities 30 (5.4) 30 (5.3) 16 (4.4) 17 (4.6)
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ed diary cards for at least 14 days were then ran-
domly assigned to receive allergen-impermeable
or placebo bedding. At randomization, the patients
completed the St. George’s Respiratory Question-
naire regarding quality of life, which was adminis-
tered again after 6 and 12 months.
During phase 1 (months 1 through 6), patients
were asked to maintain their usual inhaled cortico-
steroid therapy. They were seen at their physicians’
offices after three months and after six months;
diary cards and monitoring of the peak expiratory
flow rate were completed for the four-week peri-
od preceding the six-month visit. During phase 2
(months 7 through 12), patients were invited to par-
ticipate in a program of controlled reduction of in-
haled corticosteroid therapy, during which they
visited the study nurse monthly. The corticosteroid-
reduction protocol was based on the protocol used
in a previous study and was individually tailored,
with the dose being reduced by 25 to 50 percent
each month and the final decrement occurring in
two stages if the dose in question could be deliv-
ered in two separate inhaled doses.
 
15
 
 Asthma con-
trol was monitored on the basis of the peak expira-
tory flow rate and the level of use of the beta-agonist
inhaler.
The reduction of inhaled corticosteroid therapy
continued until either all inhaled corticosteroid use
had been discontinued or asthma control deterio-
rated according to predefined criteria (a mean peak
expiratory flow rate for the previous seven days that
was less than 85 percent of the mean value during
the run-in phase; an increase of more than six in-
halations in the daily dose of a beta-agonist for the
previous three days, as compared with the run-in
phase; or a determination by the patient, the pri-
mary care physician, or the nurse that asthma con-
trol had deteriorated sufficiently that the reduction
 
* Plus–minus values are means ±SD. Der p1 denotes 
 
Dermatophagoides pteronyssinus 1.
 
† Race was self-reported.
‡ Data were missing for one patient in the control group.
§ Data are means of within-person means.
 
¶Doses of fluticasone were doubled and subsumed under budesonide.
 
Table 1. (Continued.)
Characteristic All Patients Mite-Sensitive Patients
 
Active-Intervention
Group
(N=560)
Control
Group
(N=562)
Active-Intervention
Group
(N=366)
Control
Group
(N=366)
Diary data
Evening peak expiratory flow — liters/min§ 424.0±93.1 429.6±93.9 435.9±91.0 441.1±90.0
Diurnal variation in peak expiratory flow — %§ 4.1±7.5 4.5±8.4 4.5±7.8 4.8±8.0
Percentage of symptom-free days 24.8±28.0 24.6±29.5 25.1±27.3 23.4±29.0
Percentage of symptom-free nights 39.1±33.5 38.4±34.3 37.8±32.6 37.9±34.1
Corticosteroid used — no. (%)
Beclomethasone 458 (81.8) 438 (77.9) 309 (84.4) 291 (79.5)
Budesonide 41 (7.3) 56 (10.0) 20 (5.5) 35 (9.6)
Fluticasone 61 (10.9) 68 (12.1) 37 (10.1) 40 (10.9)
Daily dose of inhaled corticosteroids — µg
Beclomethasone
Median
Range
400
100–3200
400
50–200
400
100–2000
400
100–2000
Budesonide¶
Median
Range
1000
200–4000
1000
200–8000
1000
200–4000
1000
200–4000
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of inhaled corticosteroid therapy should be halted
or reversed). Patients in whom asthma control de-
teriorated reverted to the preceding dose of inhaled
corticosteroids and continued to receive this dose
until the end of the study.
 
outcome measures
 
The primary outcome measure for phase 1 was the
morning peak expiratory flow rate, calculated as the
mean of all measurements recorded during the four
weeks preceding the six-month visit, with control
(by analysis of covariance) for the mean of all meas-
urements recorded during the four-week run-in pe-
riod. The primary outcome measure for phase 2 was
the proportion of patients who discontinued in-
haled corticosteroid therapy.
The secondary outcome measures for phase 1
were the evening peak expiratory flow rate, the use
of beta-agonists, the scores for daytime and night-
time symptoms, the rate of exacerbation, the num-
ber of days of work missed, and the score on the
St. George’s Respiratory Questionnaire regarding
quality of life (range of scores, 0 to 100, with higher
scores indicating worse quality of life). The second-
ary outcome measure for phase 2 was the propor-
tionate reduction in the dose of inhaled cortico-
steroids by the end of the study.
 
statistical analysis
 
Differences in continuous variables measured at
base line were adjusted for the base-line level with
the use of analysis of covariance, except for the qual-
ity-of-life score, which was analyzed in terms of the
proportion of patients with improvement from base
line; this and other proportions were compared with
the use of the Pearson chi-square test. Because of
the highly skewed distribution of the number of
asthma-related days of work missed, the confidence
interval for the difference in this variable was esti-
mated with the use of a bias-corrected bootstrap
method with 1000 replicates. Proportionate reduc-
tions in the dose of inhaled corticosteroids were
compared with the use of the Mann–Whitney U test.
All analyses were performed with the use of Stata
software, version 7.0 (Stata). All primary analyses
were restricted to the mite-sensitive population,
with secondary analyses including all subjects.
On the basis of preliminary data, the standard
deviation for the 28-day mean peak expiratory flow
rate was estimated to be 112 liters per minute, and
the correlation coefficient for the 28-day means
measured six months apart was estimated to be 0.69.
On the basis of these data, a study with 750 mite-
sensitive patients who completed phase 1 would
have a statistical power of more than 90 percent (at
a 5 percent level of significance) to detect a differ-
ence of 20 liters per minute in the peak expiratory
flow rate between the groups. Furthermore, such a
study would have a statistical power of more than
90 percent to detect a 50 percent increase (from 25.0
percent to 37.5 percent) in the proportion of patients
in whom inhaled corticosteroid therapy could be
discontinued.
 
study patients
 
Figure 1 shows the numbers of patients screened
and included in the trial. Of 4654 interested patients,
2479 were screened, and 1431 were deemed to be
eligible and entered the run-in phase. At the end of
the run-in phase, 1150 patients were considered to
be suitable for the study, of whom 1122 were ran-
domly assigned to receive either allergen-imperme-
able bed covers (560 patients [the active-interven-
tion group]) or control bed covers (562 patients [the
control group]) and received a home visit. At ran-
domization, 65 percent of patients (732) were mite-
sensitive, 55 percent had pets, and 24 percent were
current smokers (Table 1). Of those who underwent
randomization, 1015 (90 percent) completed fol-
low-up at 6 months, and 932 (83 percent) completed
follow-up at 12 months. Diary data were received
from 965 of the 1015 patients at 6 months and 882
of the 932 at 12 months.
 
adherence and adverse events
 
At 12 months, 31 patients in the active-intervention
group had removed their bed covers, as compared
with 12 patients in the control group (P=0.003).
A total of 173 patients withdrew from the study (90
in the active-intervention group and 83 in the control
group), mainly for reasons unrelated to the bedding.
The frequency of adverse events was low (a total of
24 asthma-related events, 14 in the active-interven-
tion group and 10 in the control group). There was
one death due to asthma in the placebo group dur-
ing phase 1.
 
levels of exposure
 
The base-line mite-allergen levels were typical of
those seen in the United Kingdom, with approxi-
mately one quarter of beds having levels higher than
10 µg per gram of dust, one quarter having 2 to 10 µg
per gram of dust, and one half having less than 2 µg
per gram of dust (Table 1). There was no significant
results
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difference in levels of mite-allergen exposure be-
tween groups at base line (geometric mean, 1.34 µg
per gram in the active-intervention group vs. 1.36 µg
per gram in the control group). In the 10 percent
subsample, there was a significant difference be-
tween the two groups in the level of exposure to mite
allergen at 6 months (geometric mean, 0.58 µg per
gram vs. 1.71 µg per gram; P=0.01 for the difference
with adjustment for the base-line level), but not at
12 months (1.05 µg per gram vs. 1.64 µg per gram;
P=0.74 for the difference with adjustment for the
base-line level).
 
outcomes
 
The study groups were closely matched at base
line (Tables 1 and 2). At the end of phase 1, there
were no significant differences between the groups
in the primary outcome measure (morning peak ex-
piratory flow rate) or the secondary outcome meas-
ures (the use of beta-agonists, the symptom scores,
the rates of exacerbations, and the quality-of-life
scores) between the active-intervention and control
groups, either overall or among mite-sensitive pa-
tients (Table 3 and Fig. 2). There was a difference
of borderline statistical significance with regard to
the number of days of work missed, which should
be interpreted cautiously in view of the number of
comparisons performed.
A total of 480 patients in the active-intervention
group and 485 patients in the control group had
data for the morning peak expiratory flow rate at
both base line and six months. The peak expiratory
flow rate improved significantly in both groups
(from 410.7 to 419.1 liters per minute in the active-
intervention group [P<0.001] and from 417.8 to
427.4 liters per minute in the control group [P<
0.001]). After adjustment for base-line differences
with the use of analysis of covariance, there was
no significant difference between the two groups
(difference in means, active-intervention group vs.
control group, ¡1.6 liters per minute [95 percent
confidence interval, ¡5.9 to 2.7] among all patients
[P=0.46] and ¡1.5 liters per minute [95 percent con-
fidence interval, ¡6.9 to 3.9] among mite-sensitive
patients [P=0.59]).
During phase 2, 14 percent of the randomized
patients discontinued inhaled corticosteroid ther-
apy completely, with a mean reduction in the dose
of corticosteroids of almost 50 percent among the
patients who began the dose-reduction phase. This
rate of discontinuation and dose reduction was
achieved with no overall reduction in the quality-of-
life score or deterioration in the morning peak ex-
piratory flow rate (Table 4). There was no signifi-
cant difference between the groups, either overall
or among mite-sensitive patients, in either the pri-
mary outcome (percentage of all randomized pa-
tients no longer receiving inhaled corticosteroids;
relative risk of discontinuation, 1.02) or the second-
ary outcomes (mean proportionate reduction in the
dose of inhaled corticosteroids among all patients
entering the dose-reduction phase, 47 percent in the
active-intervention group vs. 48 percent in the con-
trol group) (Table 4). Further analysis of a subsam-
ple of patients with high sensitivity to mite allergen
(specific IgE level, >10 kU per liter) and a high base-
line level of mite allergen in their mattress (>10 µg
per gram of dust) revealed no significant difference
between the groups in the mean morning peak ex-
piratory flow rate during month 6 of phase 1 (mean,
416.5 liters per minute among 56 patients in the
active-intervention group vs. 424.4 liters per minute
among 74 patients in the control group; difference,
with adjustment for base-line levels, 3.12 liters per
minute [95 percent confidence interval, –10.1 to
16.3]; P=0.64).
Dust-mite-allergen–impermeable covers are wide-
ly available, recommended, and prescribed for pa-
tients with asthma. However, our study has demon-
strated that, in the absence of other mite-control
discussion
 
* Plus–minus values are means ±SD. Data for morning peak expiratory flow and 
number of puffs of relief medication are the means of within-person means. 
Data for the symptom scores are the means of within-person medians. The 
quality-of-life score is the total score on the St. George’s Respiratory Question-
 
naire (range, 0 to 100, with higher scores indicating worse quality of life).
 
Table 2. Measurements at Base Line.*
Outcome All Patients Mite-Sensitive Patients
 
Active-
Intervention
Group 
(N=560)
Control
Group 
(N=562)
Active-
Intervention
Group 
(N=366)
Control
Group 
(N=366)
Morning peak expiratory
flow (liters/min)
411.0±93.2 415.5±93.4 421.3±91.7 424.6±88.8
Puffs of a beta-agonist
Daytime
Nighttime
2.93±2.04
1.42±1.13
2.74±1.85
1.50±1.35
2.89±2.03
1.42±1.11
2.74±1.81
1.41±1.04
Symptom score
Daytime
Nighttime
1.35±0.76
0.94±0.69
1.35±0.77
0.96±0.70
1.28±0.70
0.93±0.65
1.34±0.73
0.94±0.68
Quality-of-life score 33.1±16.3 32.6±16.9 30.5±15.2 30.4±15.6
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measures, they are clinically ineffective for routine
management of adult asthma in primary care. No
effect was seen even in the subgroup of patients
with high levels of mite-specific IgE and high levels
of exposure to mite allergens.
As in most studies of allergen avoidance, we ob-
served a significant improvement in most of the
outcomes in both the active-intervention group and
the control group. Although mattress covers did
not themselves affect asthma, participation in the
study appeared to have some effect (without any
difference in the pattern of improvement between
mite-sensitive patients and those who were not sen-
sitized to mites). The morning peak expiratory flow
rate increased in both groups, the level of use of
short-acting beta-agonists was reduced, the rates of
asthma-free days and nights increased, and the qual-
ity of life improved. Concurrently, a substantial pro-
portion of patients in both groups were able to dis-
continue inhaled corticosteroid therapy or reduce
their dose of corticosteroids. The reasons for this re-
duction in use are not known. It may represent a
regression to the mean, although it is possible that
the use of an additional polyester–cotton bed cover
has a small clinical effect.
The reductions in exposure seem limited in terms
of micrograms per gram of dust, and at one year, it
appeared that the intervention had failed. However,
expression of the data in terms of the allergen con-
centration underestimates the reduction in exposure
in studies of bed covers. The total amount of aller-
gen recovered (in micrograms per square meter of
the mattress) would more adequately reflect the ef-
fect of the intervention, but the use of this measure
requires accurate weighing of dust samples, which
was not performed in this multicenter study. The
polyurethane-coated covers we used are the most
widely used type available. An experimental study
demonstrated no detectable mite-allergen passage
with the use of the same covers, in contrast to a sub-
stantial amount of leakage of allergen through the
polyester–cotton control cover.
 
16
 
 Furthermore, a
recent clinical study involving children in Denmark
in which identical bed covers were used demon-
strated a significant reduction in allergen levels over
a 12-month period when the data were expressed
in terms of the total amount of allergen recovered.
 
17
 
A Cochrane meta-analysis has attempted to de-
termine whether mite-sensitive patients with asth-
ma benefit from measures that aim to reduce their
exposure to mite allergen in their homes.
 
18
 
 Although
individual studies have been small and inconclu-
sive, the meta-analysis concluded that current chem-
ical and physical methods seem ineffective and can-
not be recommended for the treatment of asthma.
However, this meta-analysis has been criticized on
the grounds that insufficiency of the evidence does
not imply that an intervention is ineffective.
 
19,20
 
 The
results of our study are in agreement with the con-
clusions of the meta-analysis. Similarly, a recent
study reported a lack of clinical effectiveness of im-
permeable covers for bedding in patients with aller-
gic rhinitis.
 
21
 
It is difficult to conduct double-blind, placebo-
controlled trials of allergen avoidance: the combi-
nation of allergy testing and home visits may be a
potent stimulus for a change in behavior, with a re-
sulting increase in cleaning and a reduction in aller-
 
Figure 2. Mean Morning Peak Expiratory Flow Rate in 
the Active-Intervention and Control Groups at Base Line, 
6 Months, and 12 Months among All Patients (Panel A) 
and among Mite-Sensitive Patients (Panel B).
 
Data points represent the geometric means, and I bars 
the 95 percent confidence intervals.
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gen levels in the control group. In a recent study ex-
amining the effect of combined mite and cockroach
control, children were randomly assigned to an ac-
tive group, a placebo group, and an additional con-
trol group in which no home visits occurred until
the end of the study.
 
22,23
 
 The outcomes in the two
intervention groups were significantly better than
those among the children whose homes were not
visited. In our study, patients were unaware of their
mite-sensitization status, which minimized the risk
that patients in the control group might undertake
allergen-avoidance measures. Furthermore, 90 per-
cent of the participants had only one home visit,
which reduced the likelihood of a change in behav-
ior. The inclusion of a “no-treatment” control group
would not have affected the interpretation of the
data on the effect of the intervention.
Allergen levels in the United Kingdom are simi-
lar to those seen in other areas of the world with
temperate climates but are substantially lower than
those in Australia and New Zealand, for example.
Nevertheless, the lack of any benefit even in patients
with high levels of exposure to allergen suggests
that these results are likely to be widely applicable.
The high proportion of pet owners in our study
could have affected the potential benefit of a re-
duction in the level of exposure to mite allergen.
However, it is unlikely that the results of a study of
this size would be confounded by sensitivity and
exposure to other allergens. Furthermore, this was
a pragmatic clinical trial investigating the effect of
a simple, practical intervention, which mimicked
real-life clinical practice as much as possible. We
deliberately decided not to conduct a study in a care-
fully selected minority of patients, with strict crite-
ria for inclusion and exclusion and extensive inter-
vention, since the results of such a study might not
be widely applicable. It remains possible that a much
more stringent intervention in a carefully selected
group of patients could have some effect, but that
possibility was not addressed in the current study.
We have previously demonstrated that a complex
environmental intervention (including the use of al-
lergen-impermeable covers, weekly washing of bed-
ding in hot water, the use of high-efficiency vacuum
cleaners, and the replacement of carpets with hard
floors) is effective in creating a low-allergen en-
vironment for the primary prevention of asthma,
 
12
 
but this type of intervention is neither practical nor
acceptable for the majority of patients with asthma
within the context of primary care.
In the current study, the bed covers were well
tolerated, and compliance was good. Slightly more
patients in the active-intervention group than in the
control group had removed the covers by the end of
the study, but the absolute difference in numbers
was small. The slightly higher rate of noncompli-
ance is most likely attributable to the sweating that
is associated with the use of an impermeable cover.
How can we explain the discrepancy between
studies of mite avoidance in children that suggest
some benefit
 
6,8,17
 
 and the data from our study and
other studies involving adults that show no im-
provement in asthma control?
 
5,10,21
 
 Occupational
asthma may be a useful model: although early di-
agnosis and removal from the workplace where the
exposure has occurred are associated with recov-
ery,
 
24
 
 a long duration of exposure in sensitized sub-
jects leads to persistent and sometimes progressive
deterioration of asthma control, even if the expo-
sure has ceased.
 
25
 
 Thus, early detection and imme-
diate cessation of exposure may be important fac-
tors for a favorable prognosis.
In conclusion, the use of allergen-impermeable
bed covers as a single intervention for the avoidance
of mite allergen seems clinically ineffective for the
routine management of asthma in adults in primary
care. If mite avoidance is to be used in the treatment
of asthma, we need to understand better how and
where to measure the level of personal exposure to
mite allergens, how to reduce it effectively, who is
likely to benefit most, and when the intervention
should be started.
 
Supported by a grant (AM1/02/015) from the United Kingdom
National Health Service Research and Development Programme on
Asthma Management.
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